BEVESPI AEROSPHERE Drug Patent Profile

When do Bevespi Aerosphere patents expire, and what generic alternatives are available?

Bevespi Aerosphere is a drug marketed by Astrazeneca and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and ninety-four patent family members in thirty-two countries.

The generic ingredient in BEVESPI AEROSPHERE is formoterol fumarate; glycopyrrolate. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the formoterol fumarate; glycopyrrolate profile page.

DrugPatentWatch^® Generic Entry Outlook for Bevespi Aerosphere

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 28, 2030. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BEVESPI AEROSPHERE

International Patents:	194
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	13
Drug Prices:	Drug price information for BEVESPI AEROSPHERE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BEVESPI AEROSPHERE
What excipients (inactive ingredients) are in BEVESPI AEROSPHERE?	BEVESPI AEROSPHERE excipients list
DailyMed Link:	BEVESPI AEROSPHERE at DailyMed

See drug prices for BEVESPI AEROSPHERE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BEVESPI AEROSPHERE

NDA:

208294

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BEVESPI AEROSPHERE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bastiaan Driehuys	Phase 2/Phase 3
Los Angeles Biomedical Research Institute	Phase 4
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Phase 4

See all BEVESPI AEROSPHERE clinical trials

Pharmacology for BEVESPI AEROSPHERE

Drug Class	Anticholinergic Cholinergic Muscarinic Antagonist beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Cholinergic Antagonists Cholinergic Muscarinic Antagonists

US Patents and Regulatory Information for BEVESPI AEROSPHERE

BEVESPI AEROSPHERE is protected by seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes			Y

International Patents for BEVESPI AEROSPHERE

When does loss-of-exclusivity occur for BEVESPI AEROSPHERE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Montenegro

Norway

Philippines

Poland

Portugal

Russian Federation

San Marino

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BEVESPI AEROSPHERE around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	076621
Argentina	076806
Argentina	076807
Argentina	121758

Supplementary Protection Certificates for BEVESPI AEROSPHERE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0613371	SPC/GB02/033	United Kingdom		PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
0613371	2002C/022	Belgium		PRODUCT NAME: BUDESONID. MICRONIS. AND FORMOTEROL. FUMARAS DIHYDR., NATL REGISTRATION NO/DATE: 624 IS 234 F 0 20010129; FIRST REGISTRATION: SE 16047 20000825
2435025	300995	Netherlands		PRODUCT NAME: COMBINATIE VAN GLYCOPYRRONIUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER GLYCOPYRRONIUYM BROMIDE, EN FORMOTEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER FORMOTEROL FUMARAAT DIHYDRAAT; REGISTRATION NO/DATE: EU/ 1/18/1339 20181220
2435025	PA2019014	Lithuania		PRODUCT NAME: GLIKOPIROLATO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, ENANTIOMERUS AR KITUS DARINIUS) IR FORMOTEROLIO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, ENANTIOMERUS AR KITUS DARINIUS) DERINYS; REGISTRATION NO/DATE: EU/1/18/1339 20181218

BEVESPI AEROSPHERE Market Dynamics and Financial Trajectory (2018–2024): Pricing, Share, Exclusivity, and Generic/Biosimilar Risk

Last updated: July 28, 2026

Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) sits in a crowded COPD chronic maintenance market dominated by LAMA/LABA fixed-dose combinations. Financial trajectory has been shaped by (1) category maturity and payer tightening, (2) aggressive competitor substitution within LAMA/LABA and LAMA/LABA/ICS, and (3) patent-expiration-driven generic pressure in the maintenance COPD segment. By 2023–2024, the product has remained a mid-single to single-digit prescription contributor in many geographies, with revenue supported mainly by persistence among formulary-restricted patients rather than sustained share gains.

What is the market size and demand trend for Bevespi Aerosphere in COPD LAMA/LABA?

Bevespi Aerosphere is positioned for COPD maintenance as a fixed-dose combination of:

• Glycopyrrolate (LAMA)
• Formoterol fumarate (LABA)

Why LAMA/LABA demand stays resilient even as growth normalizes

COPD maintenance demand generally holds because:

• Chronic use drives baseline prescriptions
• Switching between maintenance options is payer- and symptom-driven rather than seasonal
• Inhaler adherence and formulary preference shape durable patient share

But growth rate typically moderates due to:

• Highly entrenched competitors (including dual- and triple-therapy)
• Price compression from generics in components and from class-level contracting
• Treatment guideline shifts toward triple therapy for frequent exacerbators, reducing addressable population for LAMA/LABA-only options

How payer strategy impacts Bevespi’s addressable base

Payer contracting in COPD increasingly emphasizes:

• Step edits within maintenance therapy
• Preferential coverage of specific inhalers (PBM rebates and preferred net prices)
• Narrower coverage windows for non-preferred LAMA/LABA products

That environment tends to cap unit growth for second-tier brands unless clinical differentiation or favorable formulary status is sustained.

How have competitor launches and guideline shifts changed the Bevespi revenue mix?

Bevespi competes primarily against other fixed-dose LAMA/LABA inhalers, including:

• Anoro Ellipta (umeclidinium/vilanterol)
• Stiolto Respimat (tiotropium/olodaterol)
• Utibron Neohaler (glycopyrrolate/indacaterol, different device)
• Other regional glycopyrrolate-based or formoterol-containing options

LAMA/LABA vs LAMA/LABA/ICS: the substitution pressure channel

A key revenue risk for LAMA/LABA products is step-up to triple therapy among:

• Patients with frequent exacerbations
• Patients with elevated blood eosinophils or guideline-driven steroid eligibility

This substitution redirects incremental COPD maintenance prescriptions away from dual bronchodilation toward triple inhalers, often with better payer incentives for higher-exacerbation segments.

What are the drivers of unit sales volatility for Bevespi Aerosphere?

The most material operational market drivers for a maintenance inhaler like Bevespi are:

• Formulary placement changes (PBM and payer)
• Inhaler/device preference and switching behavior
• Net price and rebate renegotiations after contract re-bids
• Channel inventory dynamics, especially around generic/component competitive events
• Seasonality of COPD exacerbations affecting physician behavior but not long-term maintenance selection

Device and adherence effects

Device experience affects:

• Time-to-therapy optimization after diagnosis
• Patient retention after early adherence trials
• Switching risk when multiple inhalers are covered equivalently

Bevespi’s impact in this channel is judged mainly by persistence rather than short-term initiation spikes.

What is the financial trajectory for Bevespi Aerosphere by geography and channel?

Because COPD inhalers are largely reimbursed through public and commercial payer systems, Bevespi’s trajectory typically differs by:

• US vs ex-US market access frameworks
• Pricing power vs reference pricing and tendering
• Competitive intensity and generic substitution in each country

US channel structure matters for COPD inhalers

In the US, brand revenue dynamics in COPD depend heavily on:

• PBM formulary status and rebate intensity
• Medicare Part D vs commercial mix
• Pharmacy benefit design (preferred tiers vs non-preferred)

When Bevespi is positioned as non-preferred relative to newer or rebate-favored products, growth usually becomes flat to declining even if clinical demand remains stable.

How does Bevespi’s pricing environment affect revenue and margins?

Inhaler brand economics are increasingly dominated by:

• Net price erosion driven by competitive contracting
• Higher rebate pressure for formulary retention
• Increased promotional spend when share is under pressure

Net price vs list price

Reported brand sales often understate the intensity of contracting because:

• List prices remain higher than net realized prices
• Competition shifts rebate rates and payer-specific net discounts quickly

That is why a “stable” prescription trend can still coincide with declining revenue, particularly as LAMA/LABA and triple-therapy portfolios broaden.

When does Bevespi lose exclusivity and what generic entry risks exist?

Bevespi’s generic entry risk hinges on:

• Patent term for fixed-dose combination and specific formulation/particle engineering
• Patent term extensions (if any)
• Carve-outs for different dosage forms, strengths, or delivery mechanisms
• Exclusivity tied to regulatory approvals and any supplementary exclusivities

What typically governs FDA-level generic timing for fixed-dose inhalers

For a fixed-dose combination like glycopyrrolate/formoterol:

• Generics generally require chemical and formulation permission through ANDA pathways
• Patent challenges are often directed at combination claims and specific formulation/process claims
• Even after core composition patents end, secondary patents (formulation, device-related delivery characteristics, particle size distribution, or manufacturing) can delay true entry

What patents protect Bevespi Aerosphere, and how strong is the patent estate?

Patent estates for combination inhalers usually include categories such as:

• Composition of matter for the combination
• Specific formulation compositions (excipients, ratios, particle properties)
• Methods of manufacturing
• Potential use/therapeutic claims

How to interpret “estate strength” for COPD inhalers

For market dynamics, estate strength translates to:

• Probability and timing of Paragraph IV certifications
• Settlement leverage and “at-risk” entry windows
• Risk that a generic bypasses key claims by design-around

Without a validated, jurisdiction-specific patent list and expiry set for Bevespi, it is not possible to quantify claim strength or exact expiry dates in this brief.

What is the Orange Book status of Bevespi Aerosphere?

Orange Book status determines:

• Which patents are listed for each NDA/strength
• Whether patents are expiring soon enough to permit first generic ANDA approval timing
• Whether Orange Book delisting or expiration aligns with observed sales flattening

Without the specific Orange Book patent listing set for each Bevespi strength, this section cannot be filled with accurate, actionable launch dates.

How do Paragraph IV challenges and settlements affect COPD brand revenue?

For mature inhalers, the standard pattern is:

• Multiple ANDA filings ahead of combination protection expiry
• Paragraph IV litigation and settlement, often with agreed entry dates
• Revenue impacts concentrated around the first authorized generic launch window

Financial impact profile

Revenue effects typically appear as:

• Early uncertainty discounts: payer shifts and wholesalers deplete brand inventory ahead of entry
• Post-entry erosion: rapid price competition and formulary switching
• Slower follow-on decline if generics remain limited to one manufacturer initially

What is the FDA regulatory status of Bevespi Aerosphere and how does it influence competition?

Bevespi’s competitive behavior is mainly driven by:

• Whether additional strengths or devices exist that protect share
• Whether alternative formulations (same actives) gain regulatory footholds
• Whether new clinical evidence supports payer coverage decisions

Regulatory status does not create direct competition unless it enables new entries (eg, additional approvals that change patent reference points or create new exclusivity).

Without NDA-level and regulatory milestone details in the cited set, this cannot be completed with hard dates.

Which competitors are most likely to pressure Bevespi sales next?

The biggest next-step pressures typically come from:

• Preferred LAMA/LABA inhalers with strong rebate profiles
• Triple-therapy inhalers that absorb exacerbation-prone cohorts
• Generic pressure on component actives that improves “least-cost” prescribing habits

Likely competitive pathways

• Formulary preference shift from Bevespi to a higher-rebate LAMA/LABA product
• Step-up from dual bronchodilation to triple therapy for exacerbators
• Increased switching to devices with better formulary coverage and patient preference

How does Bevespi compare with Anoro and Stiolto on market leverage?

Comparative advantage usually reflects:

• Patient and prescriber familiarity
• Device portfolio strength
• Contracting strength and net price support
• Margin management for brand survival during late-stage exclusivity

In practice, Anoro and Stiolto have shown the category capability to maintain patient share through:

• Strong brand presence
• Contracting aggressiveness
• Expansion within COPD prescriber pathways

This tends to compress the growth window for smaller or less-preferred brands like Bevespi over time.

What manufacturing or IP barriers could delay generic substitution?

For inhaled combination products, barriers can include:

• Device-specific delivery performance tied to formulation attributes
• Particle engineering requirements (aerosol plume characteristics, aerodynamic distribution)
• Manufacturing process controls affecting consistent delivered dose
• Secondary formulation patents that survive first composition expiry

If a generic must reformulate to achieve equivalent delivered dose characteristics, design-around can be slower and more expensive, which can delay real-world substitution even after the first eligible expiry date.

Key Takeaways

• Bevespi Aerosphere competes in a mature COPD maintenance market where payer contracting and device/persistence drive revenue more than clinical incremental adoption.
• Revenue trajectory is constrained by LAMA/LABA category normalization and continuing substitution pressure toward triple therapy in exacerbation-prone populations.
• Generic entry risk depends on the specific, strength-level patent and formulation estate timing tied to the Orange Book listings and any Paragraph IV litigation path.
• Next-market pressure is most likely from preferred LAMA/LABA competitors and triple-therapy inhalers absorbing share via payer and guideline-driven step-up patterns.

FAQs

1. What drives prescription persistence for dual LAMA/LABA inhalers like Bevespi?
   Device usability, refill adherence, and formulary persistence are the main drivers.

2. How fast do COPD inhaler revenues typically erode after generic entry?
   Fast initial erosion is common due to payer switching and price competition, followed by a slower decline depending on number of generic entrants.

3. Does Bevespi face more risk from direct generics or from therapeutic switching to triple therapy?
   Both channels matter, but therapeutic switching to triple therapy can shift the eligible patient pool even without generic entry.

4. What categories of patents usually extend protection for inhaled fixed-dose combinations?
   Formulation and manufacturing process patents often extend protection beyond the first composition claims.

5. How do rebate dynamics affect late-stage brand sales for COPD inhalers?
   Late-stage sales are sensitive to rebate renegotiations that alter net realized price and payer placement.

References (APA)

[No sources were provided in the prompt to cite for Orange Book, patent listings, exclusivity dates, litigation, or financial/revenue data for Bevespi Aerosphere.]